Targeting Cell Entry of Enveloped Viruses as an Antiviral Strategy
Abstract
:Introduction
Three Classes of Viral Fusion Proteins
Inhibitors Preventing Virus Attachment to Target Cells
Antibodies
Other attachment inhibitors
Inhibitors targeting envelope proteins
Inhibitors targeting host receptors
Viral Envelope Proteins as Targets for Entry Inhibitors
Blocking Cellular Proteins to Inhibit Virus Entry
Target: Membranes and Proteins
HCV Inhibitors Targeting Unknown Targets
Conclusions
References
- Thorley, J.A.; McKeating, J.A.; Rappoport, J.Z. Mechanisms of viral entry: Sneaking in the front door. Protoplasma 2010, 244, 15–24. [Google Scholar] [CrossRef]
- White, J.M.; Delos, S.E.; Brecher, M.; Schornberg, K. Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit. Rev. Biochem. Mol. Biol 2008, 43, 189–219. [Google Scholar] [CrossRef]
- Harrison, S.C. Viral membrane fusion. Nat. Struct. Mol. Biol 2008, 15, 690–698. [Google Scholar] [CrossRef]
- Kielian, M. Class II virus membrane fusion proteins. Virology 2006, 344, 38–47. [Google Scholar] [CrossRef]
- Kielian, M.; Rey, F.A. Virus membrane-fusion proteins: More than one way to make a hairpin. Nat. Rev. Microbiol 2006, 4, 67–76. [Google Scholar] [CrossRef]
- Colman, P.M.; Lawrence, M.C. The structural biology of type I viral membrane fusion. Nat. Rev. Mol. Cell Biol. 2003, 4, 309–319. [Google Scholar]
- Chan, D.C.; Kim, P.S. HIV entry and its inhibition. Cell 1998, 93, 681–684. [Google Scholar] [CrossRef]
- Roymans, D.; De Bondt, H.L.; Arnoult, E.; Geluykens, P.; Gevers, T.; Van Ginderen, M.; Verheyen, N.; Kim, H.; Willebrords, R.; Bonfanti, J.; Bruinzeel, W.; Cummings, M.D.; van Vlijmen, H.; Andries, K. Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proc. Natl. Acad. Sci. USA 2010, 107, 308–313. [Google Scholar]
- Porotto, M.; Yokoyama, C.; Palermo, L.M.; Mungall, B.; Aljofan, M.; Cortese, R.; Pessi, A.; Moscona, A. Viral entry inhibitors targeted to the membrane site of action. J. Virol. 2010, 84, 6760–6768. [Google Scholar] [CrossRef]
- Zhu, P.; Liu, J.; Bess, J.; Chertova, E.; Lifson, J.D.; Grisé, H.; Ofek, G.A.; Taylor, K.A.; Roux, K.H. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006, 44, 847–852. [Google Scholar]
- Melby, T.; Heilek, G.; Cammack, N.; Greenberg, M.L. Resistance to Enfuvirtide and Other HIV Entry Inhibitors. In Antimicrobial Drug Resistance; Mayers, D.L., Ed.; Humana Press: New York, NY, USA, 2009; pp. 493–506. [Google Scholar]
- Melby, T.; Westby, M. Inhibitors of Viral Entry. In Antiviral Strategies; Krausslich, R., Bartenschlager, R., Eds.; Springer-Verlag: Berlin, Heidelberg, Germany, 2009; pp. 177–202. [Google Scholar]
- Teissier, E.; Pécheur, E.I. Lipids as modulators of membrane fusion mediated by viral fusion proteins. Eur. Biophys. J. 2007, 36, 887–899. [Google Scholar] [CrossRef]
- Lamb, R.A.; Jardetzky, T.S. Structural basis of viral invasion: Lessons from paramyxovirus F. Curr. Opin. Struct. Biol. 2007, 17, 427–436. [Google Scholar] [CrossRef]
- Smith, E.C.; Popa, A.; Chang, A.; Masante, C.; Dutch, R.E. Viral entry mechanisms: The increasing diversity of paramyxovirus entry. FEBS J. 2009, 276, 7217–7227. [Google Scholar] [CrossRef]
- Rust, M.J.; Lakadamyali, M.; Zhang, F.; Zhuang, X. Assembly of endocytic machinery around individual influenza viruses during viral entry. Nat. Struct. Mol. Biol. 2004, 11, 567–573. [Google Scholar]
- Samji, T. Influenza A: Understanding the viral life cycle. Yale J. Biol. Med. 2009, 82, 153–159. [Google Scholar]
- Pielak, R.M.; Chou, J.J. Influenza M2 proton channels. Biochim. Biophys. Acta 2011, 1808, 522–529. [Google Scholar]
- Zhou, Z.; Khaliq, M.; Suk, J.; Patkar, C.; Li, L.; Kuhn, R.J.; Post, C.B. Antiviral compounds discovered by virtual screening of small-molecule libraries against dengue virus E protein. ACS Chem. Biol. 2008, 3, 765–775. [Google Scholar] [CrossRef]
- Modis, Y.; Ogata, S.; Clements, D.; Harrison, S.C. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. USA 2003, 100, 6986–6991. [Google Scholar]
- Bressanelli, S.; Stiasny, K.; Allison, S.L.; Stura, E.A.; Duquerroy, S.; Lescar, J.; Heinz, F.X.; Rey, F.A. Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J. 2004, 23, 728–738. [Google Scholar] [CrossRef]
- Krey, T.; d'Alayer, J.; Kikuti, C.M.; Saulnier, A.; Damier-Piolle, L.; Petitpas, I.; Johansson, D.X.; Tawar, R.G.; Baron, B.; Robert, B.; England, P.; Persson, M.A.A.; Martin, A.; Rey, F.A. The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog. 2010, 6, e1000762:1–e1000762:11. [Google Scholar]
- Bartosch, B.; Dubuisson, J.; Cosset, F.L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 2003, 197, 633–642. [Google Scholar] [CrossRef] [Green Version]
- Wakita, T.; Pietschmann, T.; Kato, T.; Date, T.; Miyamoto, M.; Zhao, Z.; Murthy, K.; Habermann, A.; Kräusslich, H.; Mizokami, M.; Bartenschlager, R.; Liang, T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11, 791–796. [Google Scholar]
- Evans, M.J.; von Hahn, T.; Tscherne, D.M.; Syder, A.J.; Panis, M.; Wölk, B.; Hatziioannou, T.; McKeating, J.A.; Bieniasz, P.D.; Rice, C.M. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007, 446, 801–805. [Google Scholar]
- Ploss, A.; Evans, M.J.; Gaysinskaya, V.A.; Panis, M.; You, H.; de Jong, Y.P.; Rice, C.M. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009, 457, 882–886. [Google Scholar]
- Bartosch, B.; Cosset, F.L. Cell entry of hepatitis C virus. Virology 2006, 348, 1–12. [Google Scholar] [CrossRef]
- Moradpour, D.; Penin, F.; Rice, C.M. Replication of hepatitis C virus. Nat. Rev. Microbiol. 2007, 5, 453–463. [Google Scholar] [CrossRef]
- Helle, F.; Dubuisson, J. Hepatitis C virus entry into host cells. Cell. Mol. Life Sci. 2008, 65, 100–112. [Google Scholar] [CrossRef]
- Perrault, M.; Pécheur, E.I. The hepatitis C virus and its hepatic environment: A toxic but finely tuned partnership. Biochem. J. 2009, 423, 303–314. [Google Scholar] [CrossRef]
- Blanchard, E.; Belouzard, S.; Goueslain, L.; Wakita, T.; Dubuisson, J.; Wychowski, C.; Rouillé, Y. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J. Virol. 2006, 80, 6964–6972. [Google Scholar]
- Lavillette, D.; Bartosch, B.; Nourrisson, D.; Verney, G.; Cosset, F.; Penin, F.; Pécheur, E.I. Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes. J. Biol. Chem. 2006, 281, 3909–3917. [Google Scholar]
- Backovic, M.; Jardetzky, T.S. Class III viral membrane fusion proteins. Curr. Opin. Struct. Biol. 2009, 19, 189–196. [Google Scholar] [CrossRef]
- Ramilo, O. Evolution of prophylaxis: MoAb, siRNA, vaccine, and small molecules. Paediatr. Respir. Rev. 2009, 10 (Suppl. 1), 23–25. [Google Scholar] [CrossRef]
- Hampp, C.; Saidi, A.; Winterstein, A.G. Palivizumab Utilization and Compliance: Trends in Respiratory Syncytial Virus Prophylaxis in Florida. J. Pediatr. 2010, 156, 953–959. [Google Scholar] [CrossRef]
- Huang, K.; Incognito, L.; Cheng, X.; Ulbrandt, N.D.; Wu, H. Respiratory Syncytial Virus-Neutralizing Monoclonal Antibodies Motavizumab and Palivizumab Inhibit Fusion. J. Virol. 2010, 84, 8132–8140. [Google Scholar] [CrossRef]
- Kuritzkes, D.R. HIV-1 entry inhibitors: An overview. Curr. Opin. HIV AIDS 2009, 4, 82–87. [Google Scholar] [CrossRef]
- Jacobson, J.M.; Thompson, M.A.; Lalezari, J.P.; Saag, M.S.; Zingman, B.S.; D'Ambrosio, P.; Stambler, N.; Rotshteyn, Y.; Marozsan, A.J.; Maddon, P.J.; Morris, S.A.; Olson, W.C. Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J. Infect. Dis. 2010, 201, 1481–1487. [Google Scholar] [CrossRef]
- Meuleman, P.; Hesselgesser, J.; Paulson, M.; Vanwolleghem, T.; Desombere, I.; Reiser, H.; Leroux-Roels, G. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 2008, 48, 1761–1768. [Google Scholar] [CrossRef]
- Fofana, I.; Krieger, S.E.; Grunert, F.; Glauben, S.; Xiao, F.; Fafi-Kremer, S.; Soulier, E.; Royer, C.; Thumann, C.; Mee, C.J.; McKeating, J.A.; Dragic, T.; Pessaux, P.; Stoll-Keller, F.; Schuster, C.; Thompson, J.; Baumert, T.F. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 2010, 139, 953–964. [Google Scholar]
- Timpe, J.M.; Stamataki, Z.; Jennings, A.; Hu, K.; Farquhar, M.J.; Harris, H.J.; Schwarz, A.; Desombere, I.; Roels, G.L.; Balfe, P.; McKeating, J.A. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 2008, 47, 17–24. [Google Scholar]
- Donia, M.; Cacopardo, B.; Libra, M.; Scalia, G.; McCubrey, J.A.; Nicoletti, F. New Perspectives in HCV Therapy: Entry Inhibitors. Recent Pat. Antiinfect. Drug Discov. 2010, 5, 181–194. [Google Scholar] [CrossRef]
- Eren, R.; Landstein, D.; Terkieltaub, D.; Nussbaum, O.; Zauberman, A.; Ben-Porath, J.; Gopher, J.; Buchnick, R.; Kovjazin, R.; Rosenthal-Galili, Z.; Aviel, S.; Ilan, E.; Shoshany, Y.; Neville, L.; Waisman, T.; Ben-Moshe, O.; Kischitsky, A.; Foung, S.K.H.; Keck, Z.; Pappo, O.; Eid, A.; Jurim, O.; Zamir, G.; Galun, E.; Dagan, S. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): A potential treatment to prevent HCV reinfection in liver transplant patients. J. Virol. 2006, 80, 2654–2664. [Google Scholar]
- Davis, G.L.; Nelson, D.R.; Terrault, N.; Pruett, T.L.; Schiano, T.D.; Fletcher, C.V.; Sapan, C.V.; Riser, L.N.; Li, Y.; Whitley, R.J.; Gnann, J.W. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl. 2005, 11, 941–949. [Google Scholar] [CrossRef]
- Beltramello, M.; Williams, K.L.; Simmons, C.P.; Macagno, A.; Simonelli, L.; Quyen, N.T.H.; Sukupolvi-Petty, S.; Navarro-Sanchez, E.; Young, P.R.; de Silva, A.M.; Rey, F.A.; Varani, L.; Whitehead, S.S.; Diamond, M.S.; Harris, E.; Lanzavecchia, A.; Sallusto, F. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 2010, 8, 271–283. [Google Scholar] [CrossRef]
- Jacobson, J.M.; Thompson, M.A.; Lalezari, J.P.; Saag, M.S.; Zingman, B.S.; D'Ambrosio, P.; Stambler, N.; Rotshteyn, Y.; Marozsan, A.J.; Maddon, P.J.; Morris, S.A.; Olson, W.C. Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J. Infect. Dis. 2010, 201, 1481–1487. [Google Scholar] [CrossRef]
- Wang, T.; Zhang, Z.; Wallace, O.B.; Deshpande, M.; Fang, H.; Yang, Z.; Zadjura, L.M.; Tweedie, D. L.; Huang, S.; Zhao, F.; Ranadive, S.; Robinson, B.S.; Gong, Y.; Ricarrdi, K.; Spicer, T.P.; Deminie, C.; Rose, R.; Wang, H.H.; Blair, W.S.; Shi, P.; Lin, P.; Colonno, R.J.; Meanwell, N.A. Discovery of 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J. Med. Chem. 2003, 46, 4236–4239. [Google Scholar]
- Guo, Q.; Ho, H.; Dicker, I.; Fan, L.; Zhou, N.; Friborg, J.; Wang, T.; McAuliffe, B.V.; Wang, H.H.; Rose, R.E.; Fang, H.; Scarnati, H.T.; Langley, D.R.; Meanwell, N.A.; Abraham, R.; Colonno, R.J.; Lin, P. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J. Virol. 2003, 77, 10528–10536. [Google Scholar]
- Jones, J.C.; Turpin, E.A.; Bultmann, H.; Brandt, C.R.; Schultz-Cherry, S. Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells. J. Virol. 2006, 80, 11960–11967. [Google Scholar] [CrossRef]
- Rajik, M.; Jahanshiri, F.; Omar, A. R.; Ideris, A.; Hassan, S.S.; Yusoff, K. Identification and characterisation of a novel anti-viral peptide against avian influenza virus H9N2. Virol. J. 2009, 6, 74:1–74:12. [Google Scholar]
- Helle, F.; Wychowski, C.; Vu-Dac, N.; Gustafson, K.R.; Voisset, C.; Dubuisson, J. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J. Biol. Chem. 2006, 281, 25177–25183. [Google Scholar]
- Boyd, M.R.; Gustafson, K.R.; McMahon, J.B.; Shoemaker, R.H.; O'Keefe, B.R.; Mori, T.; Gulakowski, R.J.; Wu, L.; Rivera, M.I.; Laurencot, C.M.; Currens, M.J.; Cardellina, J.H.; Buckheit, R.W.; Nara, P.L.; Pannell, L.K.; Sowder, R.C.; Henderson, L.E. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: Potential applications to microbicide development. Antimicrob. Agents Chemother. 1997, 41, 1521–1530. [Google Scholar]
- O'Keefe, B.R.; Smee, D.F.; Turpin, J.A.; Saucedo, C.J.; Gustafson, K.R.; Mori, T.; Blakeslee, D.; Buckheit, R.; Boyd, M.R. Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob. Agents Chemother. 2003, 47, 2518–2525. [Google Scholar]
- Tanaka, H.; Chiba, H.; Inokoshi, J.; Kuno, A.; Sugai, T.; Takahashi, A.; Ito, Y.; Tsunoda, M.; Suzuki, K.; Takénaka, A.; Sekiguchi, T.; Umeyama, H.; Hirabayashi, J.; Omura, S. Mechanism by which the lectin actinohivin blocks HIV infection of target cells. Proc. Natl. Acad. Sci. USA 2009, 106, 15633–15638. [Google Scholar]
- Hoorelbeke, B.; Huskens, D.; Férir, G.; François, K.O.; Takahashi, A.; Van Laethem, K.; Schols, D.; Tanaka, H.; Balzarini, J. Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope. Antimicrob. Agents Chemother. 2010, 54, 3287–3301. [Google Scholar]
- Matoba, N.; Husk, A.S.; Barnett, B.W.; Pickel, M.M.; Arntzen, C.J.; Montefiori, D.C.; Takahashi, A.; Tanno, K.; Omura, S.; Cao, H.; Mooney, J.P.; Hanson, C.V.; Tanaka, H. HIV-1 neutralization profile and plant-based recombinant expression of actinohivin, an Env glycan-specific lectin devoid of T-cell mitogenic activity. PLoS One 2010, 5, e11143. [Google Scholar]
- Chiba, H.; Inokoshi, J.; Okamoto, M.; Asanuma, S.; Matsuzaki, K.; Iwama, M.; Mizumoto, K.; Tanaka, H.; Oheda, M.; Fujita, K.; Nakashima, H.; Shinose, M.; Takahashi, Y.; Omura, S. Actinohivin, a novel anti-HIV protein from an actinomycete that inhibits syncytium formation: isolation, characterization, and biological activities. Biochem. Biophys. Res. Commun. 2001, 282, 595–601. [Google Scholar] [CrossRef]
- Chiba, H.; Inokoshi, J.; Nakashima, H.; Omura, S.; Tanaka, H. Actinohivin, a novel anti-human immunodeficiency virus protein from an actinomycete, inhibits viral entry to cells by binding high-mannose type sugar chains of gp120. Biochem. Biophys. Res. Commun. 2004, 316, 203–210. [Google Scholar] [CrossRef]
- Takahashi, A.; Inokoshi, J.; Chiba, H.; Omura, S.; Tanaka, H. Essential regions for antiviral activities of actinohivin, a sugar-binding anti-human immunodeficiency virus protein from an actinomycete. Arch. Biochem. Biophys. 2005, 437, 233–240. [Google Scholar] [CrossRef]
- Takahashi, A.; Inokoshi, J.; Tsunoda, M.; Suzuki, K.; Takenaka, A.; Sekiguchi, T.; Omura, S.; Tanaka, H. Actinohivin: specific amino acid residues essential for anti-HIV activity. J Antibiot. (Tokyo) 2010, 63, 661–66. [Google Scholar] [CrossRef]
- Bertaux, C.; Daelemans, D.; Meertens, L.; Cormier, E.G.; Reinus, J.F.; Peumans, W.J.; Van Damme, E.J.M.; Igarashi, Y.; Oki, T.; Schols, D.; Dragic, T.; Balzarini, J. Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. Virology 2007, 366, 40–50. [Google Scholar] [CrossRef]
- Kato, D.; Era, S.; Watanabe, I.; Arihara, M.; Sugiura, N.; Kimata, K.; Suzuki, Y.; Morita, K.; Hidari, K.I.P.J.; Suzuki, T. Antiviral activity of chondroitin sulphate E targeting dengue virus envelope protein. Antiviral Res. 2010, 88, 236–243. [Google Scholar] [CrossRef]
- Rocha-Perugini, V.; Montpellier, C.; Delgrange, D.; Wychowski, C.; Helle, F.; Pillez, A.; Drobecq, H.; Le Naour, F.; Charrin, S.; Levy, S.; Rubinstein, E.; Dubuisson, J.; Cocquerel, L. The CD81 partner EWI-2wint inhibits hepatitis C virus entry. PLoS One 2008, 3, e1866:1–e1866:12. [Google Scholar]
- Schuster, C.; Baumert, T.F. EWI-2wint--a host cell factor inhibiting hepatitis C virus entry. J. Hepatol. 2009, 50, 222–224. [Google Scholar] [CrossRef]
- Holzer, M.; Ziegler, S.; Albrecht, B.; Kronenberger, B.; Kaul, A.; Bartenschlager, R.; Kattner, L.; Klein, C.D.; Hartmann, R.W. Identification of terfenadine as an inhibitor of human CD81-receptor HCV-E2 interaction: synthesis and structure optimization. Molecules 2008, 13, 1081–1110. [Google Scholar] [CrossRef]
- Cianci, C.; Yu, K.; Combrink, K.; Sin, N.; Pearce, B.; Wang, A.; Civiello, R.; Voss, S.; Luo, G.; Kadow, K.; Genovesi, E.V.; Venables, B.; Gulgeze, H.; Trehan, A.; James, J.; Lamb, L.; Medina, I.; Roach, J.; Yang, Z.; Zadjura, L.; Colonno, R.; Clark, J.; Meanwell, N.; Krystal, M. Orally Active Fusion Inhibitor of Respiratory Syncytial Virus. Antimicrob. Agents Chemother. 2004, 48, 413–422. [Google Scholar]
- Cianci, C.; Langley, D.R.; Dischino, D.D.; Sun, Y.; Yu, K.; Stanley, A.; Roach, J.; Li, Z.; Dalterio, R.; Colonno, R.; Meanwell, N.A.; Krystal, M. Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion. Proc. Natl. Acad. Sci. USA 2004, 101, 15046–15051. [Google Scholar]
- Vanderlinden, E.; Göktas, F.; Cesur, Z.; Froeyen, M.; Reed, M.L.; Russell, C.J.; Cesur, N.; Naesens, L. Novel inhibitors of influenza virus fusion: Structure-activity relationship and interaction with the viral hemagglutinin. J. Virol. 2010, 84, 4277–4288. [Google Scholar]
- Russell, R.J.; Kerry, P.S.; Stevens, D.J.; Steinhauer, D.A.; Martin, S.R.; Gamblin, S.J.; Skehel, J.J. Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc. Natl. Acad. Sci. USA 2008, 105, 17736–17741. [Google Scholar]
- Poh, M.K.; Yip, A.; Zhang, S.; Priestle, J.P.; Ma, N.L.; Smit, J.M.; Wilschut, J.; Shi, P.; Wenk, M.R.; Schul, W. A small molecule fusion inhibitor of dengue virus. Antiviral Res. 2009, 84, 260–266. [Google Scholar] [CrossRef]
- Wang, Q.; Patel, S.J.; Vangrevelinghe, E.; Xu, H.Y.; Rao, R.; Jaber, D.; Schul, W.; Gu, F.; Heudi, O.; Ma, N.L.; Poh, M.K.; Phong, W.Y.; Keller, T.H.; Jacoby, E.; Vasudevan, S.G. A small-molecule dengue virus entry inhibitor. Antimicrob. Agents Chemother. 2009, 53, 1823–1831. [Google Scholar]
- Li, Z.; Khaliq, M.; Zhou, Z.; Post, C. B.; Kuhn, R.J.; Cushman, M. Design, synthesis, and biological evaluation of antiviral agents targeting flavivirus envelope proteins. J. Med. Chem. 2008, 51, 4660–4671. [Google Scholar]
- Hrobowski, Y.M.; Garry, R.F.; Michael, S.F. Peptide inhibitors of dengue virus and West Nile virus infectivity. Virol. J. 2005, 2, 49–1. [Google Scholar]
- Schmidt, A.G.; Yang, P.L.; Harrison, S.C. Peptide inhibitors of dengue-virus entry target a late-stage fusion intermediate. PLoS Pathog. 2010, 6, e1000851. [Google Scholar] [CrossRef]
- Liao, M.; Kielian, M. Domain III from class II fusion proteins functions as a dominant-negative inhibitor of virus membrane fusion. J. Cell Biol. 2005, 171, 111–120. [Google Scholar] [CrossRef]
- Chu, J.J.H.; Rajamanonmani, R.; Li, J.; Bhuvanakantham, R.; Lescar, J.; Ng, M. Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein. J. Gen. Virol. 2005, 86, 405–412. [Google Scholar] [CrossRef]
- Vaillant, A.; Juteau, J.; Lu, H.; Liu, S.; Lackman-Smith, C.; Ptak, R.; Jiang, S. Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation. Antimicrob. Agents Chemother. 2006, 50, 1393–1401. [Google Scholar] [CrossRef]
- Matsumura, T.; Hu, Z.; Kato, T.; Dreux, M.; Zhang, Y.; Imamura, M.; Hiraga, N.; Juteau, J.; Cosset, F.; Chayama, K.; Vaillant, A.; Liang, T.J. Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology 2009, 137, 673–681. [Google Scholar]
- Counihan, N.A.; Lindenbach, B.D. Gumming up the works: DNA polymers as HCV entry inhibitors. Gastroenterology 2009, 137, 427–430. [Google Scholar] [CrossRef]
- Baldick, C.J.; Wichroski, M.J.; Pendri, A.; Walsh, A.W.; Fang, J.; Mazzucco, C.E.; Pokornowski, K.A.; Rose, R.E.; Eggers, B.J.; Hsu, M.; Zhai, W.; Zhai, G.; Gerritz, S.W.; Poss, M.A.; Meanwell, N.A.; Cockett, M.I.; Tenney, D.J. A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog. 2010, 6, e1001086. [Google Scholar]
- Gilliam, B.L.; Heredia, A.; Devico, A.; Le, N.; Bamba, D.; Bryant, J.L.; Pauza, C.D.; Redfield, R.R. Rapamycin reduces CCR5 mRNA levels in macaques: Potential applications in HIV-1 prevention and treatment. AIDS 2007, 21, 2108–2110, Gilliam, B.L.; Heredia, A.; Devico, A.; Le, N.; Bamba, D.; Bryant, J.L.; Pauza, C.D.; Redfield, R.R. Rapamycin reduces CCR5 mRNA levels in macaques: Potential applications in HIV-1 prevention and treatment. AIDS 2007, 21, 2108-2110 . [Google Scholar] [CrossRef]
- Nicoletti, F.; Lapenta, C.; Lamenta, C.; Donati, S.; Spada, M.; Ranazzi, A.; Cacopardo, B.; Mangano, K.; Belardelli, F.; Perno, C.; Aquaro, S. Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin. Clin. Exp. Immunol. 2009, 155, 28–34. [Google Scholar] [CrossRef]
- Yamaya, M.; Shinya, K.; Hatachi, Y.; Kubo, H.; Asada, M.; Yasuda, H.; Nishimura, H.; Nagatomi, R. Clarithromycin inhibits type a seasonal influenza virus infection in human airway epithelial cells. J. Pharmacol. Exp. Ther. 2010, 333, 81–90. [Google Scholar] [CrossRef]
- Malakhov, M.P.; Aschenbrenner, L.M.; Smee, D.F.; Wandersee, M.K.; Sidwell, R.W.; Gubareva, L.V.; Mishin, V.P.; Hayden, F.G.; Kim, D.H.; Ing, A.; Campbell, E.R.; Yu, M.; Fang, F. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob. Agents Chemother. 2006, 50, 1470–1479. [Google Scholar]
- Triana-Baltzer, G.B.; Gubareva, L.V.; Klimov, A.I.; Wurtman, D.F.; Moss, R.B.; Hedlund, M.; Larson, J.L.; Belshe, G.B.; Fang, F. Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One 2009, 4, e7838:1–e7838:9. [Google Scholar]
- Lemon, S.M.; McKeating, J.A.; Pietschmann, T.; Frick, D.N.; Glenn, J.S.; Tellinghuisen, T.L.; Symons, J.; and Furman, P.A. Development of novel therapies for hepatitis C. Antiviral Res. 2010, 86, 79–92. [Google Scholar] [CrossRef]
- Shah, P.P; Wang, T.; Kaletsky, R.L.; Myers, M.C.; Purvis, J.E.; Jing, H.; Huryn, D.M.; Greenbaum, D.C.; Smith, A.B.; Bates, P.; Diamond, S.L. A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells. Mol. Pharmacol. 2010, 78, 319–324. [Google Scholar] [CrossRef]
- Rojek, J.M.; Pasqual, G.; Sanchez, A.B.; Nguyen, N.; de la Torre, J.; Kunz, S. Targeting the proteolytic processing of the viral glycoprotein precursor is a promising novel antiviral strategy against arenaviruses. J. Virol. 2010, 84, 573–584. [Google Scholar]
- Kido, H.; Okumura, Y.; Takahashi, E.; Pan, H.; Wang, S.; Chida, J.; Le, T.Q.; Yano, M. Host envelope glycoprotein processing proteases are indispensable for entry into human cells by seasonal and highly pathogenic avian influenza viruses. J. Mol. Genet. Med. 2008, 3, 167–175. [Google Scholar]
- Böttcher-Friebertshäuser, E.; Freuer, C.; Sielaff, F.; Schmidt, S.; Eickmann, M.; Uhlendorff, J.; Steinmetzer, T.; Klenk, H.; Garten, W. Cleavage of influenza virus hemagglutinin by airway proteases TMPRSS2 and HAT differs in subcellular localization and susceptibility to protease inhibitors. J. Virol. 2010, 84, 5605–5614. [Google Scholar]
- Cheng, G.; Montero, A.; Gastaminza, P.; Whitten-Bauer, C.; Wieland, S.F.; Isogawa, M.; Fredericksen, B.; Selvarajah, S.; Gallay, P.A.; Ghadiri, M.R.; Chisari, F.V. A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. USA 2008, 105, 3088–3093. [Google Scholar]
- Brass, V.; Bieck, E.; Montserret, R.; Wölk, B.; Hellings, J.A.; Blum, H.E.; Penin, F.; Moradpour, D. An amino-terminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A. J. Biol. Chem. 2002, 277, 8130–8139. [Google Scholar]
- Penin, F.; Brass, V.; Appel, N.; Ramboarina, S.; Montserret, R.; Ficheux, D.; Blum, H.E.; Bartenschlager, R.; Moradpour, D. Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J. Biol. Chem. 2004, 279, 40835–40843. [Google Scholar]
- Bobardt, M.D.; Cheng, G.; de Witte, L.; Selvarajah, S.; Chatterji, U.; Sanders-Beer, B.E.; Geijtenbeek, T.B.H.; Chisari, F.V.; Gallay, P. A. Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 2008, 105, 5525–5530. [Google Scholar]
- St Vincent, M.R.; Colpitts, C.C.; Ustinov, A.V.; Muqadas, M.; Joyce, M.A.; Barsby, N.L.; Epand, R.F.; Epand, R.M.; Khramyshev, S.A.; Valueva, O.A.; Korshun, V.A.; Tyrrell, D.L.J.; Schang, L.M. Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses. Proc. Natl. Acad. Sci. USA 2010, 107, 17339–17344. [Google Scholar]
- Wolf, M.C.; Freiberg, A.N.; Zhang, T.; Akyol-Ataman, Z.; Grock, A.; Hong, P.W.; Li, J.; Watson, N.F.; Fang, A.Q.; Aguilar, H.C.; Porotto, M.; Honko, A.N.; Damoiseaux, R.; Miller, J.P.; Woodson, S.E.; Chantasirivisal, S.; Fontanes, V.; Negrete, O.A.; Krogstad, P.; Dasgupta, A.; Moscona, A.; Hensley, L.E.; Whelan, S.P.; Faull, K.F.; Holbrook, M.R.; Jung, M.E.; Lee, B. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc. Natl. Acad. Sci. USA 2010, 107, 3157–3162. [Google Scholar]
- Kliger, Y.; Gallo, S.A.; Peisajovich, S.G.; Munoz-Barroso, I.; Avkin, S.; Blumenthal, R.; Shai, Y. Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage. J. Biol. Chem. 2001, 276, 1391–1397. [Google Scholar]
- Veiga, S.; Henriques, S.; Santos, N.C.; Castanho, M. Putative role of membranes in the HIV fusion inhibitor enfuvirtide mode of action at the molecular level. Biochem. J. 2004, 377, 107–110. [Google Scholar] [CrossRef]
- Matos, P.M.; Castanho, M.A.R.B.; and Santos, N.C. HIV-1 fusion inhibitor peptides enfuvirtide and T-1249 interact with erythrocyte and lymphocyte membranes. PLoS One 2010, 5, e9830–1. [Google Scholar]
- Ingallinella, P.; Bianchi, E.; Ladwa, N. A.; Wang, Y.; Hrin, R.; Veneziano, M.; Bonelli, F.; Ketas, T.J.; Moore, J.P.; Miller, M.D.; Pessi, A. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc. Natl. Acad. Sci. USA 2009, 106, 5801–5806. [Google Scholar]
- Petersen, J.; Dandri, M.; Mier, W.; Lütgehetmann, M.; Volz, T.; von Weizsäcker, F.; Haberkorn, U.; Fischer, L.; Pollok, J.; Erbes, B.; Seitz, S.; Urban, S. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat. Biotechnol. 2008, 26, 335–341. [Google Scholar] [CrossRef]
- Glebe, D.; Urban, S.; Knoop, E.V.; Cag, N.; Krass, P.; Grün, S.; Bulavaite, A.; Sasnauskas, K.; Gerlich, W. H. Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology 2005, 129, 234–245. [Google Scholar] [CrossRef]
- Gripon, P.; Cannie, I.; Urban, S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J. Virol. 2005, 79, 1613–1622. [Google Scholar] [CrossRef]
- Wang, K.; Xie, S.; Sun, B. Viral proteins function as ion channels. Biochim. Biophys. Acta 2010. [epub ahead of print]. [Google Scholar]
- Hay, A.J.; Wolstenholme, A.J.; Skehel, J.J.; Smith, M.H. The molecular basis of the specific anti-influenza action of amantadine. EMBO J. 1985, 4, 3021–3024. [Google Scholar]
- Rezak, M. Current pharmacotherapeutic treatment options in Parkinson's disease. Dis. Mon. 2007, 53, 214–222. [Google Scholar] [CrossRef]
- Chew, C.F.; Guy, A.; Biggin, P.C. Distribution and dynamics of adamantanes in a lipid bilayer. Biophys. J. 2008, 95, 5627–5636. [Google Scholar] [CrossRef]
- Bright, R.A.; Shay, D.K.; Shu, B.; Cox, N.J.; Klimov, A.I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006, 295, 891–894. [Google Scholar]
- Weinstock, D.M.; Zuccotti, G. Adamantane resistance in influenza A. JAMA 2006, 295, 934–936. [Google Scholar] [CrossRef]
- Boriskin, Y.S.; Leneva, I.A.; Pécheur, E.I.; Polyak, S.J. Arbidol: A broad-spectrum antiviral compound that blocks viral fusion. Curr. Med. Chem. 2008, 15, 997–1005. [Google Scholar] [CrossRef]
- Leneva, I.A.; Russell, R. J.; Boriskin, Y. S.; Hay, A. J. Characteristics of arbidol-resistant mutants of influenza virus: Implications for the mechanism of anti-influenza action of arbidol. Antiviral Res. 2009, 81, 132–140. [Google Scholar] [CrossRef]
- Brooks, M.J.; Sasadeusz, J.J.; and Tannock, G.A. Antiviral chemotherapeutic agents against respiratory viruses: Where are we now and what's in the pipeline? Curr. Opin. Pulm. Med. 2004, 10, 197–203. [Google Scholar] [CrossRef]
- Liu, M.; Wang, S.; Yao, W.; Wu, H.; Meng, S.; Wei, M. Pharmacokinetic properties and bioequivalence of two formulations of arbidol: An open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers. Clin. Ther. 2009, 31, 784–792. [Google Scholar] [CrossRef]
- Pécheur, E.I.; Lavillette, D.; Alcaras, F.; Molle, J.; Boriskin, Y.S.; Roberts, M.; Cosset, F.L.; Polyak, S.J. Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol. Biochemistry 2007, 46, 6050–6059. [Google Scholar]
- Haid, S.; Pietschmann, T.; Pécheur, E.I. Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition, and density of virus particles. J. Biol. Chem. 2009, 284, 17657–17667. [Google Scholar]
- Boriskin, Y.S.; Pécheur, E.I.; Polyak, S.J. Arbidol: A broad-spectrum antiviral that inhibits acute and chronic HCV infection. Virol. J. 2006, 3, 56–1. [Google Scholar]
- Teissier, E.; Zandomeneghi, G.; Loquet, A.; Lavillette, D.; Lavergne, J.P.; Montserret, R.; Cosset, F.L.; Böckmann, A.; Meier, B.H.; Penin, F. Pécheur EI: Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol. PLoS One 2011, in press. [Google Scholar]
- Liu, R.; Tewari, M.; Kong, R.; Zhang, R.; Ingravallo, P.; Ralston, R. A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. Antiviral Res. 2010, 86, 172–179. [Google Scholar] [CrossRef]
- Zhang, H.; Rothwangl, K.; Mesecar, A.D.; Sabahi, A.; Rong, L.; Fong, H.H.S. Lamiridosins, hepatitis C virus entry inhibitors from Lamium album. J. Nat. Prod. 2009, 72, 2158–2162. [Google Scholar] [CrossRef]
- Kroll, D.J.; Shaw, H.S.; Oberlies, N.H. Milk thistle nomenclature: Why it matters in cancer research and pharmacokinetic studies. Integr. Cancer Ther. 2007, 6, 110–119. [Google Scholar] [CrossRef]
- Stickel, F.; Schuppan, D. Herbal medicine in the treatment of liver diseases. Dig. Liver Dis. 2007, 39, 293–304. [Google Scholar] [CrossRef]
- Wu, J.; Lin, L.; Tsai, T. Drug-drug interactions of silymarin on the perspective of pharmacokinetics. J. Ethnopharmacol. 2009, 121, 185–193. [Google Scholar] [CrossRef]
- Polyak, S.J.; Morishima, C.; Lohmann, V.; Pal, S.; Lee, D.Y.W.; Liu, Y.; Graf, T.N.; Oberlies, N.H. Identification of hepatoprotective flavonolignans from silymarin. Proc. Natl. Acad. Sci. USA 2010, 107, 5995–5999. [Google Scholar]
- Seeff, L.B.; Curto, T.M.; Szabo, G.; Everson, G.T.; Bonkovsky, H.L.; Dienstag, J.L.; Shiffman, M.L.; Lindsay, K.L.; Lok, A.S.F.; Di Bisceglie, A.M.; Lee, W.M.; Ghany, M.G. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 2008, 47, 605–612. [Google Scholar]
- Ferenci, P.; Scherzer, T.; Kerschner, H.; Rutter, K.; Beinhardt, S.; Hofer, H.; Schöniger-Hekele, M.; Holzmann, H.; Steindl-Munda, P. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008, 135, 1561–1567. [Google Scholar] [CrossRef]
- Neumann, U.P.; Biermer, M.; Eurich, D.; Neuhaus, P.; Berg, T. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J. Hepatol. 2010, 52, 951–952. [Google Scholar] [CrossRef]
- Ahmed-Belkacem, A.; Ahnou, N.; Barbotte, L.; Wychowski, C.; Pallier, C.; Brillet, R.; Pohl, R.; Pawlotsky, J. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology 2010, 138, 1112–1122. [Google Scholar]
- Wagoner, J.; Negash, A.; Kane, O.J.; Martinez, L.E.; Nahmias, Y.; Bourne, N.; Owen, D.M.; Grove, J.; Brimacombe, C.; McKeating, J.A.; Pécheur, E.I.; Graf, T.N.; Oberlies, N.H.; Lohmann, V.; Cao, F.; Tavis, J.E.; Polyak, S.J. Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology 2010, 51, 1912–1921. [Google Scholar]
© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license ( http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Teissier, E.; Penin, F.; Pécheur, E.-I. Targeting Cell Entry of Enveloped Viruses as an Antiviral Strategy. Molecules 2011, 16, 221-250. https://doi.org/10.3390/molecules16010221
Teissier E, Penin F, Pécheur E-I. Targeting Cell Entry of Enveloped Viruses as an Antiviral Strategy. Molecules. 2011; 16(1):221-250. https://doi.org/10.3390/molecules16010221
Chicago/Turabian StyleTeissier, Elodie, François Penin, and Eve-Isabelle Pécheur. 2011. "Targeting Cell Entry of Enveloped Viruses as an Antiviral Strategy" Molecules 16, no. 1: 221-250. https://doi.org/10.3390/molecules16010221